Evidence map›Paper›PMID 34819518›Full record

Observational studyNature communications2021

Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights.

Olusegun Isaac Alatise, Gregory C Knapp, Avinash Sharma, Walid K Chatila, Olukayode A Arowolo, Olalekan Olasehinde, Olusola C Famurewa, Adeleye D Omisore, Akinwumi O Komolafe, Olaejinrinde O Olaofe and 30 more

Abstract readObservational Study
In one paragraph

Observational study in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. SOMATIC MUTATION PROFILES IN COLORECTAL CANCERS DIFFER BY POPULATION.medRxiv : the preprint server for health sciences · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Deacetylation of ACLY Mediates RNA MAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Olusegun Isaac Alatise *Faculty of Clinical Sciences, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
Gregory C Knapp *Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Avinash SharmaDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Walid K ChatilaMarie-Jose and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Olukayode A ArowoloFaculty of Clinical Sciences, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
Olalekan OlasehindeFaculty of Clinical Sciences, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
Olusola C FamurewaFaculty of Clinical Sciences, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
Adeleye D OmisoreFaculty of Clinical Sciences, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
Akinwumi O KomolafeFaculty of Clinical Sciences, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.
Olaejinrinde O OlaofeFaculty of Clinical Sciences, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria.ORCID 0000-0002-0074-6764
Aba I KatungFederal Medical Centre, Owo, Ondo State, Nigeria.
David E IbikunleFederal Medical Centre, Owo, Ondo State, Nigeria.
Adedeji A EgberongbeFederal Medical Centre, Owo, Ondo State, Nigeria.ORCID 0000-0001-8678-9249
Samuel A OlatokeDepartment of Surgery, University of Ilorin Teaching Hospital, Ilorin, Nigeria.
Sulaiman O AgodirinDepartment of Surgery, University of Ilorin Teaching Hospital, Ilorin, Nigeria.
Olusola A AdesiyunDepartment of Surgery, University of Ilorin Teaching Hospital, Ilorin, Nigeria.
Ademola AdeyeyeDepartment of Surgery, University of Ilorin Teaching Hospital, Ilorin, Nigeria.ORCID 0000-0003-1739-5013
Oladapo A KolawoleDepartment of Surgery, Ladoke Akintola University of Technology, Ogbomoso, Oyo State, Nigeria.
Akinwumi O OlakanmiDepartment of Surgery, University of Medical Sciences, Ondo, Ondo State, Nigeria.
Kanika AroraMarie-Jose and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jeremy ConstableDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ronak ShahMarie-Jose and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Azfar BasuniaMarie-Jose and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Brooke SylvesterHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chao WuHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-0260-2868
Martin R WeiserColorectal Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ken SeierDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mithat GonenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zsofia K StadlerClinical Genetics Service and the Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yelena KemelNiehaus Center for Inherited Cancer Genomics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-5042-5651
Efsevia VakianiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michael F BergerHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3882-5000
Timothy A ChanHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9265-0283
David B SolitHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6614-802X
Jinru ShiaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4351-2511
Francisco Sanchez-VegaHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2990-4893
Nikolaus SchultzHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Murray BrennanBobst International Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2358-4371
J Joshua SmithHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2538-5456
T Peter KinghamHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. kinghamt@mskcc.org.ORCID 0000-0002-3359-3186

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Understanding the molecular and phenotypic profile of colorectal cancer (CRC) in West Africa is vital to addressing the regions rising burden of disease. Tissue from unselected Nigerian patients was analyzed with a multigene, next-generation sequencing assay. The rate of microsatellite instability is significantly higher among Nigerian CRC patients (28.1%) than patients from The Cancer Genome Atlas (TCGA, 14.2%) and Memorial Sloan Kettering Cancer Center (MSKCC, 8.5%, P < 0.001). In microsatellite-stable cases, tumors from Nigerian patients are less likely to have APC mutations (39.1% vs. 76.0% MSKCC P < 0.001) and WNT pathway alterations (47.8% vs. 81.9% MSKCC, P < 0.001); whereas RAS pathway alteration is more prevalent (76.1% vs. 59.6%, P = 0.03). Nigerian CRC patients are also younger and more likely to present with rectal disease (50.8% vs. 33.7% MSKCC, P < 0.001). The findings suggest a unique biology of CRC in Nigeria, which emphasizes the need for regional data to guide diagnostic and treatment approaches for patients in West Africa.

Indexed as

AdolescentAdultAgedAged, 80 and overAge FactorsBiomarkers, TumorCase-Control StudiesColorectal NeoplasmsFemaleHigh-Throughput Nucleotide SequencingHumansLiver NeoplasmsLung NeoplasmsMaleMicrosatellite InstabilityMiddle AgedBiomarkers, Tumor

Identifiers

PMID34819518
PMCPMC8613248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.